Kunihiko Takeyama

3.5k total citations · 2 hit papers
41 papers, 2.7k citations indexed

About

Kunihiko Takeyama is a scholar working on Molecular Biology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Kunihiko Takeyama has authored 41 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Immunology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Kunihiko Takeyama's work include Lymphoma Diagnosis and Treatment (10 papers), Galectins and Cancer Biology (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Kunihiko Takeyama is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Galectins and Cancer Biology (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Kunihiko Takeyama collaborates with scholars based in United States, Japan and Argentina. Kunihiko Takeyama's co-authors include Margaret A. Shipp, Jeffery L. Kutok, Przemysław Juszczyński, Scott J. Rodig, Stefano Monti, Treeve Currie, Donna Neuberg, Bjoern Chapuy, Todd R. Golub and Evan A. O’Donnell and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Kunihiko Takeyama

37 papers receiving 2.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

2010 928 citations Michael R. Green, Stefano Monti et al. Blood profile →
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

2007 263 citations Przemysław Juszczyński, Jing Ouyang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kunihiko Takeyama United States	16	1.4k	979	936	928	374	41	2.7k
Antonella Aiello Italy	26	917 0.6×	1.4k 1.5×	1.0k 1.1×	662 0.7×	738 2.0×	61	3.1k
M Stetler-Stevenson United States	22	869 0.6×	680 0.7×	677 0.7×	735 0.8×	430 1.1×	44	2.3k
Yasuhito Terui Japan	31	1.0k 0.7×	709 0.7×	817 0.9×	461 0.5×	591 1.6×	126	2.4k
Przemysław Juszczyński Poland	24	1.9k 1.4×	1.1k 1.2×	1.6k 1.7×	1.5k 1.6×	643 1.7×	88	3.6k
Marco Herling Germany	29	1.1k 0.8×	729 0.7×	1.2k 1.3×	1.1k 1.2×	983 2.6×	118	3.0k
Katrina Wood United Kingdom	23	703 0.5×	699 0.7×	748 0.8×	770 0.8×	235 0.6×	61	2.4k
Nilanjan Ghosh United States	28	1.4k 1.0×	583 0.6×	939 1.0×	701 0.8×	424 1.1×	160	2.4k
Mamta Gupta United States	26	754 0.5×	1.2k 1.2×	824 0.9×	524 0.6×	569 1.5×	66	2.3k
Puthiyaveettil N. Raghunath United States	22	904 0.6×	948 1.0×	472 0.5×	795 0.9×	162 0.4×	37	2.4k
Sriram Balasubramanian United States	21	754 0.5×	1.1k 1.2×	590 0.6×	365 0.4×	447 1.2×	61	2.0k

Countries citing papers authored by Kunihiko Takeyama

Since Specialization

Citations

This map shows the geographic impact of Kunihiko Takeyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunihiko Takeyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunihiko Takeyama more than expected).

Fields of papers citing papers by Kunihiko Takeyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunihiko Takeyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunihiko Takeyama. The network helps show where Kunihiko Takeyama may publish in the future.

Co-authorship network of co-authors of Kunihiko Takeyama

This figure shows the co-authorship network connecting the top 25 collaborators of Kunihiko Takeyama. A scholar is included among the top collaborators of Kunihiko Takeyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunihiko Takeyama. Kunihiko Takeyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Monti, Stefano, Bjoern Chapuy, Kunihiko Takeyama, et al.. (2012). Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. Cancer Cell. 22(3). 359–372. 127 indexed citations

Ouyang, Jing, Przemysław Juszczyński, Scott J. Rodig, et al.. (2011). Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood. 117(16). 4315–4322. 68 indexed citations

Juszczyński, Przemysław, Scott J. Rodig, Jing Ouyang, et al.. (2010). MLL -Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1. Clinical Cancer Research. 16(7). 2122–2130. 28 indexed citations

Wu, David M., Neal I. Lindeman, Hidenobu Takahashi, et al.. (2009). No Evidence for the JAK2 (V617F) or JAK2 Exon 12 Mutations in Primary Mediastinal Large B-cell Lymphoma. Diagnostic Molecular Pathology. 18(3). 144–149. 8 indexed citations

Abramson, Jeremy S., Wen Chen, Przemysław Juszczyński, et al.. (2008). The heat shock protein 90 inhibitor IPI‐504 induces apoptosis of AKT‐dependent diffuse large B‐cell lymphomas. British Journal of Haematology. 144(3). 358–366. 26 indexed citations

Tobinai, Kensei, Kunihiko Takeyama, Keiko Aikawa, et al.. (2007). Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group study 9004. Cancer Science. 98(9). 1350–1357. 8 indexed citations

Tokuda, Yutaka, Tomoo Tajima, Masaru Narabayashi, et al.. (2007). Phase III study to evaluate the use of high‐dose chemotherapy as consolidation of treatment for high‐risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Science. 99(1). 145–151. 19 indexed citations

Chen, Lin‐Feng, Przemysław Juszczyński, Kunihiko Takeyama, Ricardo C.T. Aguiar, & Margaret A. Shipp. (2006). Protein Tyrosine Phosphatase Receptor-Type O Truncated (PTPROT) Regulates SYK Phosphorylation, Proximal B-Cell Receptor Signaling and Cellular Proliferation.. Blood. 108(11). 933–933. 3 indexed citations

Aguiar, Ricardo C.T., et al.. (2005). B-aggressive Lymphoma Family Proteins Have Unique Domains That Modulate Transcription and Exhibit Poly(ADP-ribose) Polymerase Activity. Journal of Biological Chemistry. 280(40). 33756–33765. 135 indexed citations

10.

Takeyama, Kunihiko & Hitoshi Ohto. (2004). PBSC mobilization. Transfusion and Apheresis Science. 31(3). 233–243. 33 indexed citations

11.

Takeyama, Kunihiko. (2003). A Dose-finding Study of Glycosylated G-CSF (Lenograstim) Combined with CHOP Therapy for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma. Japanese Journal of Clinical Oncology. 33(2). 78–85. 10 indexed citations

12.

Ishii, Katsumi, et al.. (1995). Inhibitory Effect of AL-3264, a New Antiallergic Agent, on the Prausnitz-Küstner Reaction and Leukotriene Production in Monkeys. The Japanese Journal of Pharmacology. 67(3). 263–266.

13.

Ishii, Katsumi, et al.. (1994). A Useful Method for Differential Evaluation of Anti-Inflammatory Effects Due to Cyclooxygenase and 5-Lipoxygenase Inhibitions in Mice. The Japanese Journal of Pharmacology. 65(4). 297–303. 15 indexed citations

14.

Ishii, Katsumi, et al.. (1994). Pharmacological study of ebastine, a novel histamine H1-receptor antagonist.. Folia Pharmacologica Japonica. 103(3). 121–135. 13 indexed citations

15.

Ishii, Katsumi, et al.. (1994). pharmacological study of ebastine,a novel histamine H1 receptor antagonist.. The Japanese Journal of Pharmacology. 64. 310–310. 1 indexed citations

16.

Takeyama, Kunihiko, et al.. (1993). Antihypertensive Effects of AJ-2615, a New Calcium Antagonist with α1-Adrenergic Blocking Activity in Experimental Hypertensive Animals. Journal of Cardiovascular Pharmacology. 21(5). 815–821. 8 indexed citations

17.

Tobinai, Kensei, Akio Kohno, Yasuhiro Shimada, et al.. (1993). Toxicity Grading Criteria of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology. 23(4). 250–257. 161 indexed citations

18.

Takeyama, Kunihiko, et al.. (1989). Antihypertensive effect of AJ-2615, a novel calcium entry blocker, in experimental hypertensive rats and dogs. The Japanese Journal of Pharmacology. 49. 211–211. 3 indexed citations

19.

Takeyama, Kunihiko, et al.. (1984). Renal excretion mechanism of at-2266 in dogs. Chemotherapy. 32. 154–158. 2 indexed citations

20.

Masuzawa, Takehiro, Kunihiko Takeyama, & Hitoshi Sakio. (1982). An Ecological Study of Microclimate at Timberline on Mt. Fuji I : Measurement of Diurnal Change in Air and Soil Temperature in Spring. 16. 93–101. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact